Q4 25 EPS
$1.44
BEAT +2.13%
Est. $1.41
Q4 25 Revenue
$5.70B
BEAT +1.79%
Est. $5.60B
vs S&P Since Q4 25
-31.1%
TRAILING MARKET
GEHC -26.1% vs S&P +5.0%
Full Year 2025 Results
FY 25 EPS
$4.59
BEAT +0.85%
Est. $4.55
FY 25 Revenue
$20.63B
BEAT +0.49%
Est. $20.52B
Market Reaction
Did GEHC Beat Earnings? Q4 2025 Results
GE HealthCare closed out fiscal 2025 on a solid note, posting fourth-quarter adjusted EPS of $1.44 against a $1.41 consensus estimate, a 2.13% beat, while revenue of $5.70 billion topped expectations of $5.60 billion and grew 7.1% year-over-year. The… Read more GE HealthCare closed out fiscal 2025 on a solid note, posting fourth-quarter adjusted EPS of $1.44 against a $1.41 consensus estimate, a 2.13% beat, while revenue of $5.70 billion topped expectations of $5.60 billion and grew 7.1% year-over-year. The standout driver was Pharmaceutical Diagnostics, where reported revenue surged 22.3%, complementing 6.6% growth in Imaging and broad strength across the U.S. And EMEA regions. Tariff headwinds remained the quarter's central pressure point, compressing Adjusted EBIT margin by 200 basis points to 16.7% and contributing to a decline in GAAP net income to $589.00 million from $720.00 million a year earlier. For the full year, revenue reached $20.63 billion with organic orders growth of 5.2% and a book-to-bill of 1.07x, signaling healthy underlying demand. Looking ahead to 2026, management guided for organic revenue growth of 3.0% to 4.0%, Adjusted EPS of $4.95 to $5.15, and free cash flow of approximately $1.70 billion, with tariff impacts expected to moderate from 2025 levels.
Key Takeaways
- • Pharmaceutical Diagnostics segment grew 22.3% driven by strong demand including Flyrcado rollout
- • Imaging segment grew 6.6% with strength in U.S. and EMEA markets
- • Advanced Visualization Solutions grew 5.9% year-over-year
- • Organic orders growth of 5.2% for full year with book-to-bill of 1.07x
- • Volume and price partially offset tariff expense and unfavorable mix impacts
- • Heartbeat proprietary business system driving productivity and margin expansion
GEHC YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
GEHC Revenue by Segment
With YoY comparisons, source: SEC Filings
“In our third year as a public company, we've made great strides executing our strategy focused on precision care, growth acceleration, and business optimization. We delivered a strong quarter and year with growth in Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions. This reflects healthy capital investment trends, commercial execution and demand for new products.”
— Peter Arduini, Q4 2025 Earnings Press Release
GEHC Earnings Trends
GEHC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GEHC EPS Trend
Earnings per share: estimate vs actual
GEHC Revenue Trend
Quarterly revenue: estimate vs actual
GEHC Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.99 | — | $5.13B | +2.06% |
| Q4 25 BEAT FY | $1.41 | $1.44 | +2.13% | $5.70B | +1.79% |
| FY Full Year | $4.55 | $4.59 | +0.85% | $20.63B | +0.49% |
| Q3 25 BEAT | $1.05 | $1.07 | +2.21% | $5.14B | +1.28% |
| Q2 25 BEAT | $0.92 | $1.06 | +15.51% | $5.01B | +0.84% |
| Q1 25 BEAT | $0.91 | $1.01 | +10.61% | $4.78B | +2.61% |